The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG.
Jan C. Buckner
No relevant relationships to disclose
Stephanie L. Pugh
No relevant relationships to disclose
Edward G. Shaw
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - Merck (U)
Honoraria - Merck
Research Funding - Genentech; GlaxoSmithKline; Merck
Geoffrey Barger
No relevant relationships to disclose
Stephen Coons
No relevant relationships to disclose
Peter Ricci
No relevant relationships to disclose
Dennis Bullard
No relevant relationships to disclose
Paul D. Brown
No relevant relationships to disclose
Keith Stelzer
No relevant relationships to disclose
David Brachman
No relevant relationships to disclose
John H. Suh
Consultant or Advisory Role - Varian Medical Systems
Christopher J. Schultz
No relevant relationships to disclose
Jean-Paul Bahary
No relevant relationships to disclose
Barbara Jean Fisher
Research Funding - Merck
Harold Kim
No relevant relationships to disclose
Albert D Murtha
No relevant relationships to disclose
Walter J. Curran
No relevant relationships to disclose
Minesh P. Mehta
Consultant or Advisory Role - Merck; Philips Healthcare; Tomotherapy
Stock Ownership - Accuray
Honoraria - Schering-Plough